Serial combination therapy: Is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Multiple Sclerosis

Volumn 15, Issue 8, 2009, Pages 959-964

  Bar Or, Amit ^a   Oger, J ^b   Gibbs, E ^b   Niino, M ^a   Aziz, T ^b   Renoux, C ^a   Alatab, S ^a   Shi, F D ^c   Campagnolo, D ^c   Jalili, F ^a   Rhodes, S ^c   Yamashita, T ^a   Fan, B ^a   Freedman, M S ^d   Panitch, H ^e   Arnold, D L ^a   Vollmer, T ^f  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

B cells; Combination therapy; GA reactive antibodies; Glatiramer acetate; IgG1 4; Mitoxantrone; Multiple sclerosis; Th2 immune deviation

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MITOXANTRONE;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

ADOLESCENT; ADULT; B-LYMPHOCYTES; CELLS, CULTURED; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TH1 CELLS; TH2 CELLS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69549090348     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509106230     Document Type: Article

References (33)

1. Johnson KP Brooks BR Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
2. Comi G Filippi M Wolinsky JS.; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297.
3. Filippi M Rovaris M Rocca MA Sormani MP Wolinsky JS Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001; 57: 731-733.
4. Weber MS Hohlfeld R Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007; 4: 647-653.
5. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008; 28: 5-21.
6. Duda PW Schmied MC Cook SL Krieger JI Hafler DA Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967-976.
7. Farina C Then Bergh F Albrecht H et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001; 124: 705-719.
8. Brenner T Arnon R Sela M et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152-160.
9. Arnold DL Campagnolo D Panitch H et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008; 255: 1473-1478.
10. Vollmer T Panitch H Bar-Or A et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14: 663-670.
11. Stevens TL Bossie A Sanders VM et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988; 334: 255-258.
12. Farina C Vargas V Heydari N Kumpfel T Meinl E Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002; 123: 188-192.
13. Basile E Gibbs E Aziz T Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006; 177: 161-166.
14. McDonald WI Compston A Edan G et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
15. Duddy M Niino M Adatia F et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-6099.
16. Rissoan MC Soumelis V Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-1186.
17. Harris DP Haynes L Sayles PC et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475-482.
18. Chitnis T Salama AD Grusby MJ Sayegh MH Khoury SJ. Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol 2004; 172: 4260-4265.
19. Miller A Shapiro S Gershtein R et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-121.
20. Qin Y Zhang DQ Prat A Pouly S Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 2000; 108: 201-206.
21. Tennakoon DK Mehta RS Ortega SB Bhoj V Racke MK Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006; 176: 7119-7129.
22. Jee Y Piao WH Liu R et al. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007; 125: 34-42.
23. Baecher-Allan C Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006; 212: 203-216.
24. Kantengwa S Weber MS Juillard C et al. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol 2007; 185: 123-129.
25. Kim HJ Ifergan I Antel JP et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144-7153.
26. Weber MS Starck M Wagenpfeil S Meinl E Hohlfeld R Farina C. Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127: 1370-1378.
27. Weber MS Prod'homme T Youssef S et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13: 935-943.
28. Neuhaus O Wiendl H Kieseier BC et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005; 168: 128-137.
29. Chan A Weilbach FX Toyka KV Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-158.
30. Rieger A Bar-Or A. B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol 2008; 8: 486-487.
31. Bar-Or A Calabresi P Arnold DL et al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week open-label trial. Ann Neurol 2008; 63: 395-400.
32. Hauser SL Waubant E Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
33. Piao WH Wong R Bai XF et al. Therapeutic effect of anthracene-based anticancer agent ethionamide in an animal model of multiple sclerosis. J Immunol 2007; 179: 7415-7423.